newsfilter
← Latest News
PR Newswire·

Aeglea BioTherapeutics Announces Sale of Pegzilarginase to Immedica Pharma

Global rights to pegzilarginase in development for Arginase 1 Deficiency sold to Immedica Pharma for $15 million upfront cash proceeds and up to $100 million of contingent milestone payments Marketing Authorisation